Rafehi et. al., Supplementary Figure 1

Jul 27, 2014

30 likes | 142 Views

B. Rafehi et. al., Supplementary Figure 1. A. C. Rafehi et. al., Supplementary Figure 2. Rafehi et. al., Supplementary Figure 3. Keratinocytes (20 µM). K562 (100 µM).

Share Presentation

Embed Code

Link

keratinocytes
supplementary figure
rafehi et

tuyen

Download Presentation

Rafehi et. al., Supplementary Figure 1

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

B Rafehi et. al., Supplementary Figure 1 A C
Rafehi et. al., Supplementary Figure 2
Rafehi et. al., Supplementary Figure 3 Keratinocytes (20 µM) K562 (100 µM)

Supplementary Figure 1 Abu Jawdeh et al.

Supplementary Figure 1 Abu Jawdeh et al. Quantitation of cNHE1 binding by densitometry, as determined by anti-6xHis antibody detection. Data are normalized to PI(4,5)P2 (defined as 1.0 in each experiment), and expressed as mean ± SEM. . Supplementary Figure 2 Abu Jawdeh et al.

209 views • 6 slides

Mertens et al., Supplementary Figure

Mertens et al., Supplementary Figure.

66 views • 1 slides

Supplementary Figure 1 Hori et al.

Preparation of LB-TT. Add 4 g CHAPS in a 300 (or 500) mL very clean/sterile Glass Beaker (calibrated if possible) . D issolve in 50 mL MQ water by slowly shaking using wrist movement; or better use a stirrer to mix, not to strongly…

95 views • 1 slides

Supplementary Figure 1 Lewis, et al.

Cell Death (Ramos). Untreated. Proliferation (Ramos). hIgG (crosslinked). Dacetuzumab (soluble). Dacetuzumab (crosslinked). Percent Cell Death (apoptotic + necrotic). Crosslinking Ab. Dacetuzumab (soluble). hIgG (crosslinked). Dacetuzumab (crosslinked). CD40 Ligand.

103 views • 1 slides

Nakayama et al. , Supplementary Figure 3

Nakayama et al. , Supplementary Figure 3. HNF4G/ACTB (microarray). HNF4G/ACTB (qRT-PCR). 0.035. 2.0. 0.030. 1.5. 0.025. 0.020. 1.0. 0.015. 0.010. 0.5. 0.005. 0.000. 0.0. SS043. SS043. SS043. SS043. SS043. SS043. SS046. SS046. SS046. SS046. SS046. SS046. SS049. SS049.

71 views • 1 slides

Andrade et al. - Supplementary Figure 1

Andrade et al. - Supplementary Figure 1. A. 10 20 30 40 50 60 70 80 90 100 ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|

101 views • 1 slides

Perugini et al Supplementary Figure 1

Accession. Gene Symbol. Gene Name. Direction of. Number. Regulation. Commonly Regulated. by FLT3. -. -. -. ITD (. Mizuki. , Tam) and GMR. -. -. -. V449E. (Brown). NM_009895. Cish. Cytokine inducible SH2-containing protein. . . . . . . NM_009982. Ctsc.

123 views • 1 slides

Farmer et al Supplementary Figure 1

Farmer et al Supplementary Figure 1. [ KU0058684] (  M). 1. 2. 0. 1. 0. 0. IC 50 = 1nM. 0.00001. 0.0001. KU0051529 PARP-1 IC 50 = 730nM. 0.001. 0.01. 8. 0. 0.1. 100. 10. 0. 1. % activity. 6. 0. 4. 0. 2. 0. 0. 10 -6. 10 -5. 10 -4. 10 -3. 10 -2. 10 -1. 10 0.

208 views • 7 slides

Supplementary Figure 1. Suzuki et al.

BrdU. DAPI/BrdU. 24 hrs. 24 hrs. 48 hrs. 48 hrs. 72 hrs. 72 hrs. Supplementary Figure 1. Suzuki et al. A. B. Supplementary Figure 2. Suzuki et al. p. CPD. H2AX. Merge. p. (6-4) photo. H2AX. Merge. p. XRCC1. H2AX. Merge. Supplementary Figure 3. Suzuki et al. No UV. 3 min.

187 views • 8 slides

Oka et al. supplementary Figure 1 Top

Oka et al. supplementary Figure 1 Top. DAPI. Gr-1. MERGE. Supplementary Fig. 1. Identification of neutrophils by immunostaining with anti-Gr-1 antibody. Representative specimens of the UVB-irradiated skin of PLC  +/+ mice at 24 h

168 views • 2 slides

Supplementary Figure 1 Logan et al

IP Ab. HSF1. we. Irr. p63. HSF1 Int. I. II. III. IV. V. F/l.  Pro. 1-292. 248-393. 1-42. TAD DBD Oligo. +. +. 248-393. 1-42. 1-292.  Pro. GST. Inputs. F/l. +. -. -. Pull down. Supplementary Figure 1 Logan et al.

112 views • 4 slides

Supplementary Figure 1 – Toh et. al.

12 hr. 24 hr. Taxol:. 0 hr. 24 hr + PurvA. Time (hrs): -24 0 12-15 24-27. Cell Cycle Phase: Asyn. G1/S Mitosis. Thymidine block. Thymidine Wash-out; +/-Taxol;

208 views • 8 slides

Oiva et al., Supplementary Figure.

Oiva et al., Supplementary Figure. P < 0.0001. 1000. P < 0.0001. 100. Trypsinogen-3 (  g/L). 10. 1. 0.1. Mild AP. Severe AP. Controls.

141 views • 1 slides

Supplementary Figure 5. Nikolova et al

Supplementary Figure 5. Nikolova et al.

87 views • 1 slides

Kim et al., Supplementary Figure 1.

Fig. S1. Effect of salt stress on OsCYP20-2 ectopic expression transgenic plants. a. *. *. *. *. V1 V2 T2 T3 T5. b. 0 50 100 150. V1 V2 T2 T3 T5.

101 views • 3 slides

Leimgruber et al. Supplementary Figure 1

A. TSS. S’-Y’. S-Y. B. - IFN g. 1. Resistance to MNAse. 0.1. 0.01. units:. 0. 1. 2. 4. 6. 0. 1. 2. 4. 6. 0. 1. 2. 4. 6. 3.0. -3.5 kb. S’-Y’. S-Y/TSS. 2.0. + IFN g. Relative H4Ac. 1.0. 1. Resistance to MNAse. 0.0. 0.1. 1.2. 0.01. Resistance to MNAse. units:.

123 views • 6 slides

Supplementary figure. 1 Ashino et al.

Supplementary figure. 1 Ashino et al. 6. ■ CCR6. 4. Relative expression of mRNA versus b -actin. 2. 0. Th17 polarized cells. Naive Th cells. Naive Th cells. Th17 polarized cells. DO11.10 Tg. IL-17 -/- DO11.10 Tg. Supplementary Figure 1

94 views • 1 slides

Kudo-Saito, et al Supplementary Figure 1

Kudo-Saito, et al Supplementary Figure 1. Human PBMCs. Debris Dead cells. Leukocytes. Lymphocytes. Kudo-Saito, et al Supplementary Figure 2. Mock D6 D10 F3 F5 NC. Transfectants. Normalization. (a). 0.8 0.6 0.4 0.2 0.0. Snail. Snail Slug Twist E-cadherin Fibronectin

145 views • 6 slides

Voso et al, Supplementary Figure 1

Oligonucleotide sequences and PCR conditions used for sequencing. Voso et al, Supplementary Figure 1. Exemplary sequencing reactions for all genes studied. Voso et al, Supplementary Figure 2. Time to Leukemic evolution. SRSF2-mutated. SRSF2-wild type. Probability (%). p=0.04.

164 views • 5 slides

Supplementary Figure 1 Gattolliat et al

Supplementary Figure 1 Gattolliat et al. Overall survival. Disease -free survival. High miR -487b. High miR -487b. Disease-free surviving (%). Patient surviving (%). Low miR-487b. Low miR-487b. P=0.0671. P=0.0589. Overall survival (months). Disease-Free survival (months).

101 views • 1 slides

Supplementary figure 1 Palacios et. al

E-cadherin. Transferrin. Merge. 35 °C/ 4hrs. Supplementary figure 1 Palacios et. al. 0 4 8 12 0 4 8 12. Hours of v-Src activation. Extracellular domain epitope Cytoplasmic domain epitope. { Anti-E-cadherin. Supplementary figure 2

91 views • 2 slides

Supplementary Figure 1- FUJIMURA et al.

A. Hyp-eIF5A1. Poorly Differentiated. Well Differentiated. 4. Normal. eIF5A1. 4. 3. eIF5A2. 3. C. IHC score. *. *. 2. Poorly Differentiated. Well Differentiated. IHC score. 2. GAPDH. Normal. 1. eIF5A1. eIF5A2. 1. control. 0. normal. Grade II. Grade I. 0.

133 views • 1 slides

More Related